• Professor, Department of Obstetrics and Gynecology and Department of Molecular and Integrative Physiology, University of Kansas Medical Center, USA

Warren B Nothnick PhD HCLD graduated from the Ohio State University with his Bachelor of Science in 1987, and his Master of Science in 1989.  He did his post-doctoral fellowship at the University of Kentucky and completed his PhD there in 1994.

Research in professor Nothnick’s laboratory focuses on deciphering the role of specific mediators of inflammation in the pathogenesis of endometriosis and the potential of targeting these mediators as potential therapies for endometriosis treatment. More specifically, recent emphasis has been placed on understanding the mechanisms which lead to aberrant expression of macrophage migration inhibitory factor (MIF) in endometriosis and the potential use of anti-MIF therapies in the treatment of endometriosis. His research objectives are achieved using both in vivo mouse models for endometriosis as well as in vitro systems using human cells.

Recent endometriosis publications (from a total of 40 publications) include:

  1. Nothnick WB and Zhang X. Emerging targets in endometriosis treatment. Current Women’s Health Reviews 2008;4:193-204.
  2. Nothnick WB and Zhang X. Future targets in endometriosis treatment: Targeting the endometriotic implant. Mini Rev Med Chem 2009;9:324-328.
  3. Nothnick WB. Endometriosis: in search of optimal treatment. Minerva Ginecol 2010; 62:17-31.
  4. Nothnick WB. The emerging use of aromatase inhibitors for endometriosis treatment. Reprod Biol Endocrinol 2011;9:87.
  5. Nothnick WB, Colvin A, Cheng KF, Al-Abed Y. The macrophage migration inhibitory factor antagonist, ISO-1 suppresses endometriotic implant size in mice with experimentally induced disease. J Endometriosis 2011;3:135-142.